We have previously demonstrated that nilvadipine exhibits therapeutic properties by inhibiting SYK phosphorylation, which is linked to neuroinflammation, tau phosphorylation and cognitive deficits [23]. The gene discussed is SYK; the disease is Cognitive impairment.